Alan T Cariski

Learn More
Cilostazol is a phosphodiesterase III inhibitor with antiplatelet, antithrombotic and vasodilatory effects. It raises plasma high-density lipoprotein cholesterol levels by approximately 10% and lowers plasma triglycerides by approximately 15%. Eight US/UK randomized, multicentre, double-blind, placebo-controlled trials lasting 12-24 weeks have been(More)
OBJECTIVE To compare the efficacy and safety of cilostazol in diabetic and non-diabetic patients from eight (six placebo- and two active-controlled) randomised, double-blind phase III trials. DESIGN We only included patients from the trial data set receiving cilostazol 100 mg twice daily (216 diabetic/599 non-diabetic) or placebo (220/616). Efficacy was(More)
Cembrowski et al. (1) hypothesize that the hematocrit effect (i.e., the tendency of many blood glucose meter systems toward a positive bias at low hematocrits) in the SureStep௡Flexx௡ meter (LifeScan) may have caused false hyperglyce-mia, which, when treated with insulin , may have led to some of the hypoglycemic events observed in the NICE-SUGAR(More)